MRNA injection aims to turn back the clock on aging

NCT ID NCT07544420

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an mRNA drug called aKL003 that instructs cells to produce alpha klotho, a protein linked to longevity. About 21 healthy adults aged 50-90 will receive two injections four weeks apart. The main goal is to check safety and whether the protein levels rise in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

alpha klotho mRNA (aKLmRNA, AKL003) in lipid nanoparticles

What this could lead to

If successful, this could point toward a treatment that slows or reverses aspects of aging by increasing alpha klotho protein levels.

What could go wrong

This is a very early Phase 1b safety trial with only 21 healthy volunteers. It is not designed to prove any anti-aging effect, and the treatment may fail to raise protein levels or cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GARM

    Roatán, Bay Islands, 34101, Honduras

    Contact Phone: •••-•••-•••• Email: •••••@•••••